Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A fructo-oligosaccharide prebiotic is well-tolerated in adults undergoing allogeneic hematopoietic stem cell transplantation: a phase I dose-escalation trial

Tessa. M. Andermann, Farnaz Fouladi, Fiona B. Tamburini, Bita Sahaf, Ekaterina Tkachenko, Courtney Greene, Matthew T. Buckley, Erin F. Brooks, Haley Hedlin, Sally Arai, Crystal L. Mackall, David Miklos, Anthony A. Fodor, Andrew R. Rezvani, View ORCID ProfileAmi S. Bhatt
doi: https://doi.org/10.1101/2021.04.26.21256127
Tessa. M. Andermann
1Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
MD MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Farnaz Fouladi
2Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiona B. Tamburini
3Department of Genetics, Stanford University Stanford, CA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bita Sahaf
4Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ekaterina Tkachenko
5School of Medicine, Stanford University, Stanford, CA, USA
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Courtney Greene
4Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew T. Buckley
3Department of Genetics, Stanford University Stanford, CA, USA
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin F. Brooks
8Department of Medicine, Division of Hematology, Stanford University, Stanford, CA, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haley Hedlin
9Quantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, CA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sally Arai
4Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Crystal L. Mackall
11Department of Pediatrics, Division of Hematology and Oncology, Stanford University, Stanford, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Miklos
4Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony A. Fodor
2Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: asbhatt@stanford.edu afodor@uncc.edu arezvani@stanford.edu
Andrew R. Rezvani
4Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: asbhatt@stanford.edu afodor@uncc.edu arezvani@stanford.edu
Ami S. Bhatt
15Department of Genetics, Department of Medicine, Division of Hematology, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ami S. Bhatt
  • For correspondence: asbhatt@stanford.edu afodor@uncc.edu arezvani@stanford.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Alterations of the gut microbiota after allogeneic hematopoietic cell transplantation (allo-HCT) are a key factor in the development of transplant-related complications such as graft-versus-host disease (GVHD). Interventions that preserve the gut microbiome hold promise to improve HCT-associated morbidity and mortality. Murine models demonstrate that prebiotics such as fructo-oligosaccharides (FOS) may increase gut levels of short-chain fatty acids (SCFAs) such as butyrate, and consequently induce proliferation of immunomodulatory CD4+ FOXP3+ T-regulatory cells (Tregs), that impact GVHD risk.

Methods We conducted a pilot Phase I trial to assess the investigate the maximum tolerated dose of FOS in patients undergoing reduced-intensity (RIC) allo-HCT (n=15) compared to concurrent controls (n=16). We administered FOS starting at pretransplant conditioning and continuing for a total of 21 days. We characterized the gut microbiome using shotgun metagenomic sequencing, measured stool SCFAs using LC-MS, and determined peripheral T-cell concentrations using CyTOF.

Results We found that FOS was safe and well-tolerated at 10g per day without significant adverse effects in patients undergoing reduced-intensity conditioning allo-HCT. Community-level gut microbiota composition was significantly different on the day of transplant (day 0) between patients receiving FOS compared to concurrent controls, however FOS-associated alterations of the gut microbiota were not sustained after transplant. Although the impact of FOS was fleeting, transplantation itself impacted a substantial number of taxa over time. In our small pilot trial, no significant differences were observed in gut microbial metabolic pathways, stool SCFAs, or in peripheral Tregs although Tregs trended higher in those patients who received FOS. Early alterations in gut microbiota composition in those receiving FOS are especially intriguing although it remains unclear what impact this has on outcomes following transplantation and larger studies are required to investigate the use of prebiotics in HCT recipients.

Conclusions FOS is well-tolerated at 10g per day in patients undergoing RIC allo-HCT.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT02805075

Funding Statement

This work was supported in part by the Amy Strelzer Manasevit Award from the National Marrow Donor Program, the National Center for Advancing Translational Science, Clinical and Translational Science Awards KL2TR001083 and UL1TR001085 and the Society of Blood and Marrow Transplantation New Investigator Award (T.M.A.). F.B.T was supported in part by the National Science Foundation Graduate Research Fellowship. A.S.B. was supported by NCI KO8 CA184420, the Amy Strelzer Manasevit Award, a Damon Runyon Clinical Investigator Award, and the V Foundation scholar award.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All participants meeting eligibility criteria were informed about the study and required to provide written informed consent under IRB #37979 (PI: Andrew Rezvani) prior to undergoing study-related procedures; patients not receiving FOS had consented to have their stool and blood samples collected under IRB #8903 (PI: David Miklos). The protocol and informed consent documents were reviewed and approved by the Stanford human subjects review board and the Stanford Cancer Institute. The study was performed in accordance with the Declaration of Helsinki.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data not included in the manuscript will be available by request to the corresponding authors. All metagenomic data will be uploaded to the SRA.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 28, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A fructo-oligosaccharide prebiotic is well-tolerated in adults undergoing allogeneic hematopoietic stem cell transplantation: a phase I dose-escalation trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A fructo-oligosaccharide prebiotic is well-tolerated in adults undergoing allogeneic hematopoietic stem cell transplantation: a phase I dose-escalation trial
Tessa. M. Andermann, Farnaz Fouladi, Fiona B. Tamburini, Bita Sahaf, Ekaterina Tkachenko, Courtney Greene, Matthew T. Buckley, Erin F. Brooks, Haley Hedlin, Sally Arai, Crystal L. Mackall, David Miklos, Anthony A. Fodor, Andrew R. Rezvani, Ami S. Bhatt
medRxiv 2021.04.26.21256127; doi: https://doi.org/10.1101/2021.04.26.21256127
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
A fructo-oligosaccharide prebiotic is well-tolerated in adults undergoing allogeneic hematopoietic stem cell transplantation: a phase I dose-escalation trial
Tessa. M. Andermann, Farnaz Fouladi, Fiona B. Tamburini, Bita Sahaf, Ekaterina Tkachenko, Courtney Greene, Matthew T. Buckley, Erin F. Brooks, Haley Hedlin, Sally Arai, Crystal L. Mackall, David Miklos, Anthony A. Fodor, Andrew R. Rezvani, Ami S. Bhatt
medRxiv 2021.04.26.21256127; doi: https://doi.org/10.1101/2021.04.26.21256127

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Transplantation
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (551)
  • Anesthesia (135)
  • Cardiovascular Medicine (1751)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (656)
  • Epidemiology (10790)
  • Forensic Medicine (8)
  • Gastroenterology (586)
  • Genetic and Genomic Medicine (2939)
  • Geriatric Medicine (287)
  • Health Economics (532)
  • Health Informatics (1921)
  • Health Policy (834)
  • Health Systems and Quality Improvement (744)
  • Hematology (291)
  • HIV/AIDS (628)
  • Infectious Diseases (except HIV/AIDS) (12509)
  • Intensive Care and Critical Care Medicine (687)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2789)
  • Nursing (151)
  • Nutrition (432)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1460)
  • Ophthalmology (443)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (363)
  • Primary Care Research (336)
  • Psychiatry and Clinical Psychology (2635)
  • Public and Global Health (5349)
  • Radiology and Imaging (1008)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (725)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)